Type 1 Diabetes Clinical Trial
Official title:
Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes (DILfrequency)
Type 1 diabetes (T1D) is the most common severe autoimmune disease worldwide and is caused by
the body's immune destruction of its own insulin producing pancreatic beta cells leading to
insulin deficiency and development of elevated blood sugars. Currently, medical management of
T1D focuses on intensive insulin replacement therapy to limit complications (retinopathy,
nephropathy, neuropathy); nevertheless clinical outcomes remain suboptimal. There are
intensive efforts to design novel immunotherapies that can arrest the autoimmune process and
thereby preserve residual insulin production leading to fewer complications and better
clinical outcomes.
Genetics are in part the cause of T1D and the majority of genes contributing to T1D produce
proteins involved in immune regulation (called "tolerance"). A key player in immune tolerance
is a molecule called interleukin-2 (IL-2) which enhances the ability of cells called T
regulatory (Treg) cells to suppress the destruction the insulin producing beta cells.
Aldesleukin is a human recombinant IL-2 product produced by recombinant DNA technology using
a genetically engineered E. coli strain expressing an analogue of the human IL-2 gene. There
is substantial data to suggest that ultra-low doses (ULD) of IL-2 (aldesleukin) can arrest
the autoimmune mediated destruction of pancreatic beta cells by the induction of functional
Treg cells.
The former study "Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes"
(DILT1D) (NCT 01827735) was a single dose mechanistic study designed to establish the doses
of IL-2 (aldesleukin) required to induce a minimal Treg increase (0.1 fold from baseline) or
to induce a slightly larger Treg increase (0.2 fold from baseline) (maximal increase).
Following on from the DILT1D study, the goal of the DILfrequency study is to use an adaptive
design to determine the optimal dose and frequency of ULD IL-2 (aldesleukin) to maximize Treg
function by frequently injecting ultra-low doses of IL-2 (aldesleukin). The responsiveness of
each T1D participant to a particular frequency of IL-2 (aldesleukin) administration informs
the frequency of dosing given to the next patient. This strategy focuses on improving the
function of regulatory T cells that are exquisitely sensitive to IL-2 (aldesleukin).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
| Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
| Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
| Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
| Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
| Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
| Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
| Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
| Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
| Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
| Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
| Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
| Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
| Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
| Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
| Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
| Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
| Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
| Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
| Completed |
NCT02855307 -
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
|
Phase 2 |